Merck Life Science proudly announces the groundbreaking of its new, state-of-the-art Bioprocessing Production Center in Daejeon, representing our largest investment in Asia Pacific to date, at €300 million. This significant milestone, achieved together with colleagues, customers, and government officials, underscores our deep commitment to both South Korea and the greater Asia Pacific region.

The new facility will play a pivotal role in supporting the biotech and pharmaceutical industries by developing and manufacturing vaccines, cell and gene therapies, and protein-based therapies. This expansion will undoubtedly accelerate the healthcare ecosystem in the region, bolstering South Korea’s ambitious goal to become a top-five global vaccine producer.

“We’re building a vibrant science and tech community in South Korea, with our presence extending from Seoul to Songdo and now to Daejeon,” said Spokesperson at Merck Life Science. “We selected Daejeon for this expansion because it is known as the ‘City of Science,’ reflecting Korea’s unwavering commitment to innovation and the advancement of science. With a significant portion of South Korea’s national funding for R&D focused in this rapidly growing biotech community, Daejeon is the ideal location to enhance our manufacturing capabilities.”

We extend our heartfelt thanks to Minister Cheong, Daejeon Mayor Lee, Ambassador Schmidt, Council President Lee, and KAIST President Lee for joining us and supporting our team in South Korea. Your partnership has been instrumental in making today a reality and a success.

Once complete, this center will serve as a prime example of how, together with our partners, we are impacting life and health through science.